Yahoo Finance

JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring ...
Seeking Alpha

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum ...

– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination product ...
BioWorld

Beetles sing money tune as Verrica result punches cantharidin ticket to ride

Verrica Pharmaceuticals Inc.'s positive phase III data from its pivotal Cantharidin Application in Molluscum Patients-1 (CAMP-1) and CAMP-2 trials with lead candidate VP-102 at the American Academy of ...
Monthly Prescribing Reference

NDA Submitted for Topical Molluscum Contagiosum Therapy

The Food and Drug Administration (FDA) has accepted for filing the New Drug Application for cantharidin 0.7% topical solution (VP-102; Verrica Pharmaceuticals) for the treatment of molluscum ...
Mena FN

Verrica Pharmaceuticals Announces Fda Approval Of Ycanthtm (Cantharidin) Topical Solution As The First Fda Approved Treatment Of Pediatric And Adult Patients With Molluscum ...

(MENAFN- GlobeNewsWire - Nasdaq) – Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTHTM is a ...